Strategic ambiguities with "stem cells"
July 2009. While many ethical questions surrounding the use of stem cells have been satisfactorily answered, a number of unresolved methodological and technical issues hamper applications in the pharmacceutical industry. Where are the stumbling blocks of today? What is Merck’s and Merck Serono’s approach, and with what prospects? Bernd Kirschbaum, Head of Global Discovery and Early Development for Merck Serono and points to strategic ambiguities in technology development.Reading time: 4 min
Read Now: |
Other articles recommended
B2Bioworld offers you background information
Stem Cells: a discovery tool and a potential therapeutic modality
Jonathan K. C. Knowles, at the time Head of Roche Group Research - open access
Boehringer Ingelheim: Embryonic stem cells and animal models
Andreas Barner, Chairman Boehringer Ingelheim and Head of Pharma Research
Bayer AG: New stakes in stem cells
Andreas Busch, Head of Global Drug Discovery on results, technology platforms, and expectations
Thinking Further About Stem Cells - Viewed from Systems Biology
Leroy Hood, President Institute for Systems Biology, Seattle, Washington (US)
Stem Cells – Failings and Deliveries
Patenting Stem Cells – Behind the Front Stages
A legal approach solving problems with patentability